A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
The study evaluates the long-term safety and tolerability of VX-445 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous or heterozygous for the F508del mutation
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Peoria, Illinois 61637, United States
Boston, Massachusetts 02114, United States
Minneapolis, Minnesota 55404, United States
Cleveland, Ohio 44106, United States
Toledo, Ohio 43606, United States
Milwaukee, Wisconsin 53226, United States
Benite Cedex, France
Erlangen, Germany
Heidelberglaan, Netherlands